Ardelyx, Inc. (ARDX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.78+1.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ARDX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to increase IBSRELA product revenue with a full-year 2026 guidance range of $350 to $370 million.
Stated as a priority in 2 of last 2 quarters. IBSRELA revenue grew from $70.1 million in 2026-Q1 to $86.2 million in 2026-Q2, reflecting strong demand. Management revised full-year 2026 guidance to $350-$370 million, showing delivery on growth with a positive trajectory.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Full-year 2026 revenue guidance for IBSRELA revised to be between $350 and $370 million.”
“IBSRELA is on the path to becoming a blockbuster by achieving at least one billion dollars in revenue in 2029 with continued strong growth thereafter.”
Maintain and grow XPHOZAH product revenue with full-year 2026 guidance between $110 and $120 million.
Stated as a priority in 2 of last 2 quarters. XPHOZAH revenue increased from $23.3 million in 2026-Q1 to $31.9 million in 2026-Q2, supporting the reiterated full-year guidance of $110-$120 million. The trajectory is delivering consistent growth.
“Full-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million.”
“XPHOZAH revenue between $110.0 and $120.0 million.”
Complete enrollment in the Phase 3 ACCEL trial for IBSRELA by end of 2026 and announce topline data in second half of 2027.
Stated as a priority in 2 of last 2 quarters. Management reports ACCEL Phase 3 trial enrollment is on track for completion by end of 2026 with topline data expected in second half of 2027. This timeline matches prior statements, indicating consistent progress.
“IBSRELA is being evaluated for CIC in a Phase 3 trial, ACCEL, on track to complete enrollment by end of 2026 and announce topline data in second half of 2027.”
“In January 2026, dosed first patient in ACCEL and expect to complete enrollment by end of 2026 with topline data read out in second half of 2027.”
Control operating expenses with revised full-year 2026 guidance to remain below $500 million.
Newly stated in 2026-Q2. Management revised operating expense guidance to remain below $500 million for 2026. Recent quarterly SG&A expenses increased to $101.4 million in 2026-Q2 from $83.2 million in 2026-Q1, indicating ongoing investment but with a target to control total annual expenses.
“OPEX guidance revised to be below $500 million.”
Advance IND-enabling studies for RDX10531 with potential broad therapeutic applications.
Stated as a priority in 2 of last 2 quarters. Management continues IND-enabling studies for RDX10531, aiming for broad therapeutic applications. No financial metrics yet, but the consistent mention indicates ongoing development progress.
“RDX10531, the next-generation NHE3 inhibitor, is currently being tested in IND-enabling studies.”
“RDX10531 is currently being tested in IND-enabling studies with potential broad applications.”
Over the trailing year it converted 0.86x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.